Your trusted source for investing success

Tag: vision

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy

Apellis Pharmaceuticals (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today will provide an update with 18-month data on its Phase 2 trial (FILLY) of its complement C3 inhibitor, APL-2, in patients with geographic atrophy (GA) associated with age-related macular degeneration

YDreams Global Closes Private Placement

YDreams Global Closes Private Placement

YDreams Global Interactive Technologies Inc. (TSXV: YD) (OTC Pink: YDRMF) (FSE: A2AP0L) (“YDreams Global” or the “Company) has closed a non-brokered private placement for gross proceeds of $2,750,000. The first tranche consists of 4,376,665 units at $0.15.

Eyecarrot Announces Commercial Launch of Binovi in Spain

Eyecarrot Announces Commercial Launch of Binovi in Spain

Eyecarrot Innovations Corp (TSXV:EYC) is pleased to announce the full commercial release of BinoviTM into the Spanish market. The full launch will be announced at the 2018 Sociedad Internacional de Optometria del Desarrollo y Comportamiento (International Society of Developmental and Behavioural Optometry) Conference in March.

Relevium Commences Trading on OTCQB

Relevium Technologies (OTCQB:RLLVF) is pleased to announce that it has commenced trading on the OTCQB under the symbol RLLVF.

As quoted in the press release:
Aurelio Useche, President and CEO of Relevium stated: “We have been focused on an industry and technologies that, from our analytics resonate very well in the U.S. market as that is

5 Artificial Intelligence Stocks

5 Artificial Intelligence Stocks

The AI sector is poised to grow by a CAGR of 52 percent between 2017 and 2025, making it a hot industry for investors to jump in on. Here’s a look at 5 AI-related stocks.

Hiku Brands Awarded Prized Retail Cannabis License in Manitoba

Hiku Brands Awarded Prized Retail Cannabis License in Manitoba

Hiku Brands Company Ltd. (“Hiku” or the “Company”) (CSE: HIKU), is pleased to announce that its wholly-owned subsidiary, Tokyo Smoke, with participation by BOBHQ, has been conditionally awarded one of four master retail licenses (the “License”) in Manitoba’s highly competitive Request for Proposal (“RFP”) process for the right to operate

Fintech Stocks in Canada

Fintech Stocks in Canada

While the current state of the Canadian fintech market pales in comparison to the rest of the world, its uses and adoptions are expected to increase in the country. Here are nine fintech stocks in Canada.

How to Invest in Robotics

How to Invest in Robotics

It’s no secret that the robotics industry is transforming the global economy. Here’s a brief overview of how to invest in this growing market.

Zinc Prices Have Hit a Decade High


See why zinc prices might rally in 2018 in our free report


Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy

URL: https://investingnews.com/daily/life-science-investing/biotech-investing/apellis-pharmaceuticals-announces-18-month-results-phase-2-study-filly-apl-2-geographic-atrophy/